Skip to content

Advertisement

  • Hypothesis
  • Open Access

Metformin promotes cholesterol efflux in macrophages by up-regulating FGF21 expression: a novel anti-atherosclerotic mechanism

Lipids in Health and Disease201615:109

https://doi.org/10.1186/s12944-016-0281-9

©  The Author(s). 2016

  • Received: 20 April 2016
  • Accepted: 15 June 2016
  • Published:

Keywords

  • Metformin
  • FGF21
  • Macrophage
  • ABCA1
  • ABCG1
  • Cholesterol efflux

Metformin is widely used as a glucose-lowering agent in patients with type 2 diabetes (T2D). Recently, several studies have confirmed that metformin possessed multiple cardiovascular protective effects such as decreasing cardiovascular mortality, attenuating adverse cardiac and vascular remodeling and ameliorating atherosclerosis [1–3]. Hong et al. [4] in a multicenter, randomized, double-blind, placebo-controlled clinical trial found treatment with metformin for 3 years substantially reduced major cardiovascular events in a median follow-up of 5.0 years compared with glipizide in type 2 diabetes patients who had a history of coronary artery disease. Forouzandeh et al. [5] demonstrated metformin treatment significantly attenuated high-fat diet-induced atherosclerosis in apolipoprotein E-knockout (ApoE −/−) mice. These studies suggest metformin could ameliorate atherosclerosis, but the anti-atherosclerotic mechanism of metformin remains to be fully clarified.

Previous studies reported that metformin could decrease plasma cholesterol levels in diabetic and non-diabetic patients beyond its glucose-lowering effect [6–9], and the lipid-lowering effect of metformin was also confirmed in a meta-analysis of randomized controlled trials (RCTs) [10]. Besides, it was found that metformin treatment could lower inflammation markers levels in patients at high risk of cardiovascular disease and restore impaired HDL-mediated cholesterol efflux from macrophages due to glycation [11, 12]. These effects may contribute to the anti-atherosclerotic properties of metformin.

The deposition of excessive cholesterol in macrophages plays a key role in atherosclerotic plaque formation, thus removal of excess cholesterol from macrophages may attenuate and even regress the atherosclerosis [13]. It has been identified that removal of cholesterol from macrophages was mediated by several transmembrane transporters, including adenosine triphosphate binding cassette (ABC) transporters A1 and G1 [14]. Yvan-Charvet et al. [15] evidenced that combined deficiency of Abca1 and Abcg1 in macrophages severely damaged cholesterol efflux and accelerated atherosclerosis in low-density lipoprotein receptor-knockout (Ldlr -/-) mice. Bochem et al. [16] demonstrated that carriers of ABCA1 loss-of-function mutations presented with lower cholesterol efflux capacity and higher atherosclerotic burden compared with age and sex-matched controls. Conversely, increased expression of ABCA1 and ABCG1 was involved in redistribution of cholesterol from inner to outer leaflet of the plasma membrane, facilitating cholesterol efflux from cholesterol-loaded macrophages [17]. Overexpression of ABCA1 in macrophages increased cholesterol efflux by about 60 % (P = 0.0006) and reduced atherosclerotic plaques by about 68 % (P = 0.0008) in Ldlr -/- mice fed a Western-type diet for 12 weeks [18]. Thus, ABCA1- and ABCG1-driven cholesterol efflux in macrophages was a key regulator in anti-atherosclerosis.

Fibroblast growth factor (FGF) 21, a member of FGF subfamily and mainly secreted by liver and adipose tissue, is a novel metabolic regulator with multiple cardioprotective efficacy [19]. It was found that FGF21 deficiency caused a marked exacerbation of atherosclerotic plaque formation in ApoE −/− mice [20]. Moreover, previous studies also demonstrated that FGF21 could activate ABCA1 and ABCG1 expression of macrophages and in turn promoted cholesterol efflux in macrophages [21, 22], suggesting up-regulation of FGF21 exerted function of reducing atherosclerotic plaques. Intriguingly, Nygaard et al. [23] found metformin significantly increased FGF21 expression in both rat and human hepatocytes. Another study showed metformin could increase serum FGF21 levels both in mice and human [24]. Thus, we speculate metformin stimulates ABCA1 and ABCG1 expression via up-regulation of FGF21.

Taken together, we hypothesize metformin increases FGF21 expression, and subsequently promotes expression of ABCA1 and ABCG1 in macrophages, which promotes cholesterol efflux from macrophages and attenuated atherosclerotic plaques. Further exploring cardioprotective mechanism of metformin will be useful for insight into novel therapeutic targets.

Abbreviations

ABC, adenosine triphosphate binding cassette; ABCA1, adenosine triphosphate binding cassette transporters A1; ABCG1, adenosine triphosphate binding cassette transporters G1; ApoE, apolipoprotein E; FGF, fibroblast growth factor; FGF21, fibroblast growth factor 21; Ldlr, low-density lipoprotein receptor; RCT, randomized controlled trial; T2D, type 2 diabetes.

Declarations

Acknowledgments

None

Authors’ contributions

XL conceived the idea; FL wrote the manuscript; FL, YG and GR collected and read the literature; XL read through and corrected the manuscript. All authors read and approved the final manuscript.

Competing interests

The authors declare that they have no competing interests.

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Authors’ Affiliations

(1)
Department of Internal Cardiovascular Medicine, The Second Xiangya Hospital of Central South University, 139 Middle Renmin Road, Changsha, 410011, People’s Republic of China

References

  1. Burla AK, Lobato NS, Fortes ZB, Oigman W, Neves MF. Cardiac fibrosis and vascular remodeling are attenuated by metformin in obese rats. Int J Cardiol. 2013;165:483–7.View ArticlePubMedGoogle Scholar
  2. Romero SP, Andrey JL, Garcia-Egido A, et al. Metformin therapy and prognosis of patients with heart failure and new-onset diabetes mellitus. A propensity-matched study in the community. Int J Cardiol. 2013;166:404–12.View ArticlePubMedGoogle Scholar
  3. Roussel R, Travert F, Pasquet B, et al. Metformin use and mortality among patients with diabetes and atherothrombosis. JAMA Intern Med. 2010;170:1892–9.View ArticleGoogle Scholar
  4. Hong J, Zhang Y, Lai S, et al. Effects of metformin versus glipizide on cardiovascular outcomes in patients with type 2 diabetes and coronary artery disease. Diabetes Care. 2013;36:1304–11.View ArticlePubMedPubMed CentralGoogle Scholar
  5. Forouzandeh F, Salazar G, Patrushev N, et al. Metformin beyond diabetes: pleiotropic benefits of metformin in attenuation of atherosclerosis. J Am Heart Assoc. 2014;3:e001202.View ArticlePubMedPubMed CentralGoogle Scholar
  6. Xu T, Brandmaier S, Messias AC, et al. Effects of Metformin on Metabolite Profiles and LDL Cholesterol in Patients With Type 2 Diabetes. Diabetes Care. 2015;38:1858–67.View ArticlePubMedGoogle Scholar
  7. Wu RR, Zhang FY, Gao KM, et al. Metformin treatment of antipsychotic-induced dyslipidemia: an analysis of two randomized, placebo-controlled trials. Mol Psychiatry. 2016. doi:10.1038/mp.2015.221 [Epub ahead of print].Google Scholar
  8. Ma J, Liu LY, Wu PH, Liao Y, Tao T, Liu W. Comparison of metformin and repaglinide monotherapy in the treatment of new onset type 2 diabetes mellitus in China. J Diabetes Res. 2014;2014:294017.PubMedPubMed CentralGoogle Scholar
  9. Glueck CJ, Fontaine RN, Wang P, et al. Metformin reduces weight, centripetal obesity, insulin, leptin, and low-density lipoprotein cholesterol in nondiabetic, morbidly obese subjects with body mass index greater than 30. Metabolism. 2001;50:856–61.View ArticlePubMedGoogle Scholar
  10. Wulffele MG, Kooy A, de Zeeuw D, Stehouwer CD, Gansevoort RT. The effect of metformin on blood pressure, plasma cholesterol and triglycerides in type 2 diabetes mellitus: a systematic review. J Intern Med. 2004;256:1–14.View ArticlePubMedGoogle Scholar
  11. Krysiak R, Okopien B. The effect of metformin on monocyte secretory function in simvastatin-treated patients with impaired fasting glucose. Metabolism. 2013;62:39–43.View ArticlePubMedGoogle Scholar
  12. Matsuki K, Tamasawa N, Yamashita M, et al. Metformin restores impaired HDL-mediated cholesterol efflux due to glycation. Atherosclerosis. 2009;206:434–8.View ArticlePubMedGoogle Scholar
  13. Feig JE, Hewing B, Smith JD, Hazen SL, Fisher EA. High-density lipoprotein and atherosclerosis regression: evidence from preclinical and clinical studies. Circ Res. 2014;114:205–13.View ArticlePubMedPubMed CentralGoogle Scholar
  14. Rosenson RS, Brewer Jr HB, Davidson WS, et al. Cholesterol efflux and atheroprotection: advancing the concept of reverse cholesterol transport. Circulation. 2012;125:1905–19.View ArticlePubMedPubMed CentralGoogle Scholar
  15. Yvan-Charvet L, Ranalletta M, Wang N, et al. Combined deficiency of ABCA1 and ABCG1 promotes foam cell accumulation and accelerates atherosclerosis in mice. J Clin Invest. 2007;117:3900–8.PubMedPubMed CentralGoogle Scholar
  16. Bochem AE, van Wijk DF, Holleboom AG, et al. ABCA1 mutation carriers with low high-density lipoprotein cholesterol are characterized by a larger atherosclerotic burden. Eur Heart J. 2013;34:286–91.View ArticlePubMedGoogle Scholar
  17. Pagler TA, Wang M, Mondal M, et al. Deletion of ABCA1 and ABCG1 impairs macrophage migration because of increased Rac1 signaling. Circ Res. 2011;108:194–200.View ArticlePubMedGoogle Scholar
  18. Van Eck M, Singaraja RR, Ye D, et al. Macrophage ATP-binding cassette transporter A1 overexpression inhibits atherosclerotic lesion progression in low-density lipoprotein receptor knockout mice. Arterioscler Thromb Vasc Biol. 2006;26:929–34.View ArticlePubMedGoogle Scholar
  19. Degirolamo C, Sabba C, Moschetta A. Therapeutic potential of the endocrine fibroblast growth factors FGF19, FGF21 and FGF23. Nat Rev Drug Discov. 2016;15:51–69.View ArticlePubMedGoogle Scholar
  20. Lin Z, Pan X, Wu F, et al. Fibroblast growth factor 21 prevents atherosclerosis by suppression of hepatic sterol regulatory element-binding protein-2 and induction of adiponectin in mice. Circulation. 2015;131:1861–71.View ArticlePubMedPubMed CentralGoogle Scholar
  21. Shang W, Yu X, Wang H, et al. Fibroblast growth factor 21 enhances cholesterol efflux in THP-1 macrophage-derived foam cells. Mol Med Rep. 2015;11:503–8.PubMedGoogle Scholar
  22. Lin XL, He XL, Zeng JF, et al. FGF21 increases cholesterol efflux by upregulating ABCA1 through the ERK1/2-PPARgamma-LXRalpha pathway in THP1 macrophage-derived foam cells. DNA Cell Biol. 2014;33:514–21.View ArticlePubMedGoogle Scholar
  23. Nygaard EB, Vienberg SG, Orskov C, Hansen HS, Andersen B. Metformin stimulates FGF21 expression in primary hepatocytes. Exp Diabetes Res. 2012;2012:465282.View ArticlePubMedPubMed CentralGoogle Scholar
  24. Kim KH, Jeong YT, Kim SH, et al. Metformin-induced inhibition of the mitochondrial respiratory chain increases FGF21 expression via ATF4 activation. Biochem Biophys Res Commun. 2013;440:76–81.View ArticlePubMedGoogle Scholar

Copyright

© The Author(s). 2016

Advertisement

Lipids in Health and Disease

ISSN: 1476-511X